Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc senior vice president Julia Madsen reported a routine tax-withholding transaction tied to vesting equity awards. On June 4, 2026, 195 ordinary shares were disposed of at $212.24 per share to cover taxes due on 542 restricted shares that vested that day.
After this withholding, Madsen directly holds 12,257 ordinary shares of STERIS, including 4,190 restricted shares as of June 8, 2026. These restricted shares are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.
STERIS plc SVP & GM, AST Kenneth E. Kohler reported a routine tax-related share disposition. On June 4, 2026, 150 ordinary shares were withheld from 513 restricted shares that vested, to cover taxes based on the NYSE closing price of $212.24 per share. After this, he directly holds 11,332 ordinary shares, including 3,972 restricted shares scheduled to lapse between 2027 and 2029.
STERIS plc senior executive Mary Clare Fraser reported a routine tax-withholding transaction related to restricted share vesting. On June 4, 2026, 600 ordinary shares were withheld at $212.24 per share to cover taxes on 1,360 restricted shares that vested that day. After this tax-withholding disposition, she directly owns 13,716 ordinary shares, including 5,359 restricted shares. The restricted shares are scheduled to lapse in stages between June 2027 and June 2029, reflecting ongoing equity-based compensation rather than an open-market sale.
STERIS plc President and CEO Daniel A. Carestio reported a net sale of 4,428 Ordinary Shares in open‑market transactions. He sold 3,054 shares at $214.64 on June 4, 2026 and 1,374 shares at $212.00 on June 5, 2026.
On June 4, 2026, 1,889 shares were withheld to cover taxes on 4,283 restricted shares that vested, a non‑market tax-withholding disposition. After these transactions, he directly owns 63,647 Ordinary Shares. As of June 8, 2026, 39,893 of these shares remain restricted and are scheduled to vest in tranches through June 4, 2029.
STERIS plc Senior Vice President and CFO Karen L. Burton reported a routine tax-withholding transaction. On June 4, 2026, 90 ordinary shares were withheld at $212.24 per share from 306 restricted shares that vested to cover required taxes, not an open-market sale.
After this transaction, Burton directly holds 13,184 ordinary shares, including 9,282 restricted shares as of June 8, 2026, which are scheduled to lapse in stages between October 1, 2026 and June 4, 2029.
STERIS plc senior vice president and general counsel John Adam Zangerle reported a routine tax-withholding transaction related to vested stock. On June 3, 2026, 365 ordinary shares were withheld from 1,252 restricted shares that vested, using the NYSE closing price of $210.19 per share to cover required taxes. After this withholding, he directly holds 37,079 ordinary shares. As of June 3, 2026, 9,615 of these shares remain restricted, with restrictions scheduled to lapse in several tranches between June 4, 2026 and June 4, 2029.
STERIS plc executive Renato Tamaro reported a routine tax-related share withholding tied to restricted stock vesting. On June 3, 2026, 64 ordinary shares valued at $210.19 per share were withheld to cover taxes from 217 restricted shares that vested that day. After this transaction, Tamaro directly owned 6,259 ordinary shares, of which 1,626 remained restricted and will vest in scheduled tranches between June 2026 and June 2029. This event reflects compensation and tax mechanics rather than an open-market sale.
STERIS plc senior executive Julia Madsen reported a routine tax-withholding transaction linked to restricted share vesting. On June 3, 2026, 239 ordinary shares valued at $210.19 per share were withheld from 666 restricted shares that vested, to cover taxes determined under applicable laws using the NYSE closing price.
After this withholding, Madsen directly held 12,452 ordinary shares, including 4,732 restricted shares as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.
STERIS plc senior executive Kenneth E. Kohler reported a routine tax-withholding transaction related to restricted stock vesting. On June 3, 2026, 184 ordinary shares were withheld at a value of $210.19 per share to cover taxes on 630 restricted shares that vested that day.
After this tax-withholding disposition, Kohler directly holds 11,482 ordinary shares of STERIS, of which 4,485 remain restricted as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029, reflecting ongoing equity-based compensation rather than open-market trading.
STERIS plc senior executive handles tax withholding on vested shares. SVP & Chief HRO Mary Clare Fraser had 311 ordinary shares withheld on June 3, 2026 to cover taxes on 835 restricted shares that vested, based on the NYSE closing price that day. After this non-market tax-withholding disposition, she directly holds 14,316 ordinary shares, including 6,719 restricted shares scheduled to lapse in stages between June 4, 2026 and June 4, 2029.